Neue Wege zur Früherkennung, Prognoseabschätzung und Therapie maligner Tumoren des Gastrointestinaltraktes

Zusammenfassung

Gastrointestinale Tumoren sind mit einer weltweiten Zahl von ca. 2 Millionen Neuerkrankungen und 1,2 Millionen Sterbefällen pro Jahr die häufigsten malignen Tumoren des Menschen. Sie sind meistens Erkrankungen des Seniums. Bei kontinuierlich steigender Lebenserwartung in den westlichen Industrienationen nimmt ihre relative und absolute Häufigkeit kontinuierlich zu. Nur so ist zu erklären, warum das distale Magenkarzinom bei abnehmender Inzidenz eine steigende Prävalenz aufweist. Gastrointestinale Tumoren werden auch zukünftig ein immanentes klinisches und gesundheitsökonomisches Problem darstellen. Ihre Prognose ist oft schlecht, da sie meistens zu spät diagnostiziert werden und die therapeutischen Optionen dann nur noch eingeschränkt sind. Um diesen Problemen zu begegnen, müssen Strategien entwickelt werden, die eine Identifikation von Risikopatienten und Tumoren im Frühstadium erlauben und auf eine breitere Akzeptanz in der Bevölkerung stoßen. Es sollten prognostische und prädiktive Biomarker entwickelt und in der Klinik eingesetzt werden, die auch im Stande sind, eine Therapie in den verschiedenen Stadien einer Tumorerkrankung zu lenken.

Abstract

Tumours of the gastrointestinal tract are the single largest group of malignant tumours of humans accounting for approximately 2 million new cases and over 1.2 million deaths annually. They are most commonly a disease of the elderly, and their relative and absolute frequency will rise continuously due to an ageing population. This explains why the prevalence of gastric cancer increases in spite of a decreasing incidence. Gastrointestinal tumours will remain a major clinical and health economical challenge. The prognosis is often dismal. Most of these cancers are diagnosed in an advanced stage, which prohibits curative treatment and limits treatment options. In order to circumvent these problems, we need to develop strategies that allow identification of at-risk patients and tumours at an early stage, and raise the compliance in the general population for screening programmes. There is a great need in clinics for prognostic and predictive biomarkers that are able to tailor patient treatment at different stages of the disease.

Darm - Magenkarzinom - Magen - Ösophaguskarzinom - Ösophagus

esophagus - stomach - colon - cancer

Literatur

• 1 Lander E S, Linton L M, Birren B. et al . Initial sequencing and analysis of the human genome.  Nature. 2001;  409 860-921
• 2 Venter J C, Adams M D, Myers E W. et al . The sequence of the human genome.  Science. 2001;  291 1304-1351
• 3 Röcken C, Ebert M P, Roessner A. Proteomics in pathology, research and practice.  Pathol Res Pract. 2004;  200 69-82
• 4 Hohenberger P, Gretschel S. Gastric cancer.  Lancet. 2003;  362 305-315
• 5 Thibodeau S N, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon.  Science. 1993;  260 816-819
• 6 Gayther S A, Gorringe K L, Ramus S J. et al . Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.  Cancer Res. 1998;  58 4086-4089
• 7 Guilford P, Hopkins J, Harraway J. et al . E-cadherin germline mutations in familial gastric cancer.  Nature. 1998;  392 402-405
• 8 Nishisho I, Nakamura Y, Miyoshi Y. et al . Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.  Science. 1991;  253 665-669
• 9 Kinzler K W, Nilbert M C, Su L K. et al . Identification of FAP locus genes from chromosome 5q21.  Science. 1991;  253 661-665
• 10 Aaltonen L A, Peltomaki P, Leach F S. et al . Clues to the pathogenesis of familial colorectal cancer.  Science. 1993;  260 812-816
• 11 Ionov Y, Peinado M A, Malkhosyan S. et al . Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.  Nature. 1993;  363 558-561
• 12 Lindblom A, Tannergard P, Werelius B. et al . Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer.  Nature Genet. 1993;  5 279-282
• 13 Han H J, Yanagisawa A, Kato Y. et al . Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer.  Cancer Res. 1993;  53 5087-5089
• 14 Jones P A, Baylin S B. The Epigenomics of Cancer.  Cell. 2007;  128 683-692
• 15 Herman J G, Baylin S B. Gene silencing in cancer in association with promoter hypermethylation.  New Engl J Med. 2003;  349 2042-2054
• 16 Ahmed F E. Molecular markers that predict response to colon cancer therapy.  Expert Rev Mol Diagn. 2005;  5 353-375
• 17 Schmiegel W, Pox C, Adler G. et al . S3-Guidelines Conference „Colorectal Carcinoma” 2004.  Z Gastroenterol. 2004;  42 1129-1177
• 18 Locker G Y, Hamilton S, Harris J. et al . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.  J Clin Oncol. 2006;  24 5313-5327
• 19 Wagner A D, Schneider P M, Fleig W E. The role of chemotherapy in patients with established gastric cancer.  Best Pract Res Clin Gastroenterol. 2006;  20 789-799
• 20 Chan K C, Lo Y M. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers.  Br J Cancer. 2007;  96 681-685
• 21 Ebert M P, Korc M, Malfertheiner P. et al . Advances, challenges, and limitations in serum-proteome-based cancer diagnosis.  J Proteome Res. 2006;  5 19-25
• 22 Ebert M P, Meuer J, Wiemer J C. et al . Identification of gastric cancer patients by serum protein profiling.  J Proteome Res. 2004;  3 1261-1266
• 23 Ebert M P, Kruger S, Fogeron M L. et al . Overexpression of cathepsin B in gastric cancer identified by proteome analysis.  Proteomics. 2005;  5 1693-1704
• 24 Ebert M P, Röcken C. Molecular screening of gastric cancer by proteome analysis.  Eur J Gastroenterol Hepatol. 2006;  18 847-853
• 25 Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer.  Best Pract Res Clin Gastroenterol. 2006;  20 651-674
• 26 Ebert M P, Model F, Mooney S. et al . Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.  Gastroenterology. 2006;  131 1418-1430
• 27 Dziadziuszko R, Hirsch F R, Varella-Garcia M. et al . Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization - why, when, and how?.  Clin Cancer Res. 2006;  12 4409 s-4415 s
• 28 Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update.  Mol Diagn Ther. 2006;  10 345-352
• 29 Hayashida Y, Honda K, Osaka Y. et al . Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling.  Clin Cancer Res. 2005;  11 8042-8047
• 30 Wardelmann E, Thomas N, Merkelbach-Bruse S. et al . Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.  Lancet Oncol. 2005;  6 249-251
• 31 Drug-Diagnostic Co-Development .Concept Paper. Department of Health and Human Services. Food and Drug Administration April 2005 http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf
• 32 Greef van der J, Hankemeier T, McBurney R N. Metabolomics-based systems biology and personalized medicine: moving towards n= 1 clinical trials?.  Pharmacogenomics. 2006;  7 1087-1094
• 33 Longley D B, Allen W L, Johnston P G. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.  Biochim Biophys Acta. 2006;  1766 184-196
• 34 Allen W L, Johnston P G. Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.  Pharmacogenomics. 2005;  6 603-614
• 35 Allen W L, Coyle V M, Johnston P G. Predicting the outcome of chemotherapy for colorectal cancer.  Curr Opin Pharmacol. 2006;  6 332-336
• 36 Catalano V, Baldelli A M, Giordani P. et al . Molecular markers predictive of response to chemotherapy in gastrointestinal tumors.  Crit Rev Oncol Hematol. 2001;  38 93-104
• 37 Leichman C G. Predictive and prognostic markers in gastrointestinal cancers.  Curr Opin Oncol. 2001;  13 291-299
• 38 Parissenti A M, Hembruff S L, Villeneuve D J. et al . Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.  Anticancer Drugs. 2007;  18 499-523
• 39 Sargent D J, Wieand H S, Haller D G. et al . Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.  J Clin Oncol. 2005;  23 8664-8670
• 40 Carl-McGrath S, Lendeckel U, Ebert M. et al . Ectopeptidases in tumour biology: A review.  Histol Histopathol. 2006;  21 1339-1353
• 41 Röcken C, Lendeckel U, Dierkes J. et al . The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.  Clin Cancer Res. 2005;  11 2526-2530
• 42 Röcken C, Röhl F W, Diebler E. et al . The Angiotensin II/Angiotensin II-Receptor-System Correlates with Nodal Spread in Intestinal-type Gastric Cancer.  Cancer Epidemiol Biomarkers Prev. 2007;  16 1206-1212